News

• Oxurion to Participate in Needham Virtual Healthcare Conference
  03/28/2022 / 08:00 - GlobeNewswire
•  
• Oxurion Publishes 2021 Annual Report
  03/25/2022 / 22:11 - GlobeNewswire
•  
• Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG
  03/17/2022 / 19:00 - GlobeNewswire
•  
• Oxurion Successfully Closes EUR >10 Million in Private Placement
  03/07/2022 / 10:00 - GlobeNewswire
•  
• OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US AND EUROPEAN HEALTHCARE INVESTORS IN A PRIVATE EQUITY PLACEMENT
  03/03/2022 / 12:15 - GlobeNewswire
•  
• OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US AND EUROPEAN HEALTHCARE INVESTORS IN A PRIVATE EQUITY PLACEMENT
  03/03/2022 / 08:00 - GlobeNewswire
•  
• Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
  02/22/2022 / 08:01 - GlobeNewswire
•  
• Oxurion NV announces 2021 Full Year Results and 2022 Outlook
  02/22/2022 / 08:00 - GlobeNewswire
•  
• Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference
  02/14/2022 / 08:00 - GlobeNewswire
•  
• Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference
  02/11/2022 / 08:00 - GlobeNewswire
•  
• Oxurion to Participate in the 2022 BIO CEO and Investor Conference
  02/08/2022 / 08:00 - GlobeNewswire
•  
• OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference
  01/18/2022 / 08:00 - GlobeNewswire
•  
• Oxurion Provides Update on Clinical Pipeline Progress
  01/07/2022 / 07:00 - GlobeNewswire
•  
• OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
  01/04/2022 / 18:00 - GlobeNewswire
•  
• Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
  11/30/2021 / 07:00 - GlobeNewswire